Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
The firm saw total revenues of $859,526 for the three months ended Dec. 31, 2018 compared to $995,226 in the same period of 2017.
Funds raised will help accelerate commercialization of the firm's InVisionFirst-Lung liquid biopsy test and support development of the firm's platform for new indications
Under the agreement, Bellwether researchers will join the team advancing Guardant's LUNAR early cancer detection and monitoring assays.
The firms plan to use Natera's cell-free DNA liquid biopsy assay to monitor patients' response to Amal's cancer vaccine in combination with immunotherapy.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
The ctDNA test will be covered for all US fee-for-service Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.